<https://helda.helsinki.fi>

Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors

Bryk, Saara

2018-10

Bryk , S , Pukkala , E , Färkkilä , A , Heikinheimo , M , Unkila-Kallio , L & Riska , A 2018 , ' Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors ' , International Journal of Gynecological Cancer , vol. 28 , no. 8 , pp. 1529-1534 . <https://doi.org/10.1097/IGC>

<http://hdl.handle.net/10138/311747>

<https://doi.org/10.1097/IGC.0000000000001333>

cc_by_nc

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

**Other Primary Malignancies Among Women With Adult-type Ovarian
Granulosa Cell Tumors**

Saara Bryk, MD, PhD^{1,2}, Eero Pukkala, PhD^{3,4}, Anniina Färkkilä, MD, PhD^{1,2},
Markku Heikinheimo, MD, PhD^{2,5}, Leila Unkila-Kallio, MD, PhD¹, Annika Riska,
MD, PhD¹

1 Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital
2 Children's Hospital, University of Helsinki and Helsinki University Hospital
3 Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer
Research, Helsinki, Finland
4 Faculty of Social Sciences, University of Tampere, Tampere, Finland
5 Department of Pediatrics, Washington University School of Medicine, St Louis
Children's Hospital, St Louis, Missouri

Corresponding author

Saara Bryk, M.D., Ph.D.
Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital,
PO Box 140, 00290 Helsinki, Finland
e-mail: saara.bryk@hus.fi
Tel: +358503559848

Keywords Granulosa Cell Tumor, Sex Cord-Stromal Tumors, Second Primary
Malignancy, Second Primary Cancer, Ovarian Cancer Epidemiology

Word count 2,490

Acknowledgments We thank Tiina Hakanen for invaluable assistance with the cancer
registry data. This study received funding from the Finnish Cancer Foundation and
University of Helsinki Research Funds.

The authors declare no conflicts of interest.

1 **Abstract**

2

3 **Objective** To determine the incidence of new primary malignancies after adult-type
4 granulosa cell tumor (AGCT), and the incidence of AGCT after breast and uterine
5 cancer using nationwide population-based registry data.

6 **Methods** We identified all patients diagnosed with AGCT in 1968-2013 from the
7 Finnish Cancer Registry (n=986). The number of subsequent primary malignancies
8 among women with AGCT, and the number of AGCTs in women with previous
9 breast or uterine cancer were compared with the expected number of cases, and
10 expressed as Standardized Incidence Ratios (SIRs).

11 **Results** There were 122 cases of subsequent cancers diagnosed at least six months
12 after the primary diagnosis of AGCT (SIR 1.09, 95% CI 0.91-1.3). Particularly, the
13 observed number of cancers of the soft tissue (SIR 4.13, 95% CI 1.33-12.8), thyroid
14 (SIR 3.42, 95% CI 1.54-7.62), and leukemia (SIR 2.67, 95% CI 0.98-5.82) exceeded
15 the number of expected cases. The SIR for breast cancers after AGCT was 1.26 (95%
16 CI 0.92-1.73), and the SIR for AGCT after breast cancer 1.59 (95% CI 1.04-2.29).
17 The risk for subsequent AGCT was more than two-fold in breast cancer patients less
18 than 50 years of age, and over 15 years after primary diagnosis.

19 **Conclusions** There is an increased risk for thyroid and soft tissue cancer as well as
20 leukemia after AGCT, which may be associated with late effects of carcinogenic
21 treatments and possibly shared risk factors. After breast cancer, the risk for AGCT
22 was higher, which may indicate shared hormonal etiology.

23

24

Introduction

Adult type-granulosa cell tumors of the ovary (AGCTs) account for 5% of all ovarian neoplasms, and constitute the majority of sex cord-stromal tumors¹. The recently reported age-adjusted (World Standard) incidence rates (truncated to age categories 20 years or older) of AGCT average around 0.6-0.8/100,000 women, and peak after menopause². AGCTs are characterized by their estrogen-secreting ability, although it has been estimated that approximately 30% of these tumors do not secrete estradiol, likely due to lack of theca cells in the tumor stroma¹. A single somatic point mutation in the transcription factor *FOXL2* (402C-G) is the pathognomonic molecular feature for AGCTs³. Otherwise, the etiological factors remain unknown, although some studies have suggested a possible hormonal background for these tumors^{4, 5}. According to current knowledge, there is no hereditary predisposition for the development of AGCT.

The diagnosis is usually made at an early stage, partly due to symptoms related to hormone secretion, and the disease tends to run an indolent course. Excessive exposure to tumor-derived estrogen among these patients leads to an increased risk of concomitant endometrial pathology and endometrial cancer⁶⁻⁹. There are, however, only a few studies focusing on other primary malignancies in women with AGCT^{10, 11}. In general, the risk of other primary malignancies after ovarian cancer is associated with either inherent genetic or lifestyle-related extrinsic risk factors, or carcinogenic treatment regimens¹²⁻¹⁴. As other, particularly endocrine-related cancers may share etiological factors with AGCTs, it is of interest to study the potential association of these cancers, especially breast and uterine cancer. The object

of our study was to evaluate the incidence of all other primary cancers after AGCT, as well the incidence of AGCT after breast or uterine cancer.

Materials and methods

In this retrospective cohort study, we identified all patients diagnosed with AGCT in Finland during 1968-2013 from the Finnish Cancer Registry (FCR). The FCR is a high-quality, population-based registry relying on unique personal identity codes. The personal identity code is a specific means of identification, which remains unchanged throughout the person's lifetime, and has been used in Finland since the 1960s. Physicians, hospitals, and pathology and hematology laboratories in Finland are obliged to report all malignant tumors to the FCR, resulting in a nearly complete registration of all cancer cases¹⁵. Information on vital status and emigration was obtained from the Population Register Center, which is directly linked to the FCR information.

AGCTs were retrieved from the registry applying the ICD topography code C56.9 with morphology codes M8620/1, 8620/3, 8621/1, and 8621/3. The incidence rates of AGCT during the follow-up period were calculated, and adjusted for age to the World Standard Population. All patients were followed up for second primary cancer from the date of first diagnosis (1968-2013) to the date of death, date of migration, or until December 31st, 2013. In order to identify concomitant cancers and surveillance bias, the analyses were carried out in two subgroups: 1) all subsequent tumors after AGCT, and 2) all subsequent tumors except those occurring within six months after AGCT. Subsequent primary tumors were grouped in 18 categories based on cancer site, and included ICD-codes C00-96, D32-33, D42-43, D45-47, and D76

(mouth/pharynx, digestive organs, respiratory organs, breast, female genitalia, urinary organs, melanoma of the skin, skin (other than melanoma), eye, thyroid gland, other endocrine glands, bone, soft tissues, mesothelioma, autonomic nervous system, brain/central nervous system, lymphoid/hematopoietic tissue, other/not defined). The number of new primary malignant tumors among women with previous AGCT was compared with the expected number of cases calculated from the accumulated person-years and incidence rates for the national population, stratified by age and year of diagnosis.

Secondly, we analyzed the number of subsequent AGCTs in women with a first primary breast or uterine cancer (ICD C54 and C50), and compared it with the expected number of AGCTs. These analyses were likewise performed separately on all subsequent AGCTs as well as those occurring within 6 months of the primary cancer diagnoses. The ratio of observed to expected cases was defined as the Standardized Incidence Ratio (SIR), and 95% confidence intervals (CI) were calculated. The SIRs were also stratified for time since first primary cancer diagnosis (0-4 years, 5-14 and 15+ years after the diagnosis of first primary tumor), for age at the first primary cancer diagnosis (<50 or 50 years or older), and in breast cancer also for the invasion status (localized vs. non-localized).

The ethics committee of Helsinki University Hospital (HUH) and the National Supervisory Authority for Welfare and Health approved the study.

Results

In 1968-2013, a total of 986 women in Finland were diagnosed with AGCT. The age-adjusted (World Standard) incidence varied between 0.4 and 0.9 per 100,000 women, with approximately 20 cases each year (Figure 1). The logarithmic trend line suggests a decreasing trend in the incidence of AGCT over the 45-year study period.

After the diagnosis of AGCT, 122 cases of new primary malignant tumors were recorded, resulting in a 12.4% rate of second malignancies among AGCT patients. The expected number was 111.7 (SIR 1.09, 95% CI 0.91-1.3) (Table 1). If also cancers diagnosed within six months of AGCT were included, the total rate was 13.9% and SIR 1.19 (95% CI 1-1.41, $p=0.04$). The SIR for these cancers only was 5.00 (95% CI 2.80-8.23). The median interval between the diagnosis of AGCT and second primary tumor was 19.2 years (range 0.02-45.6 years). In a minimum time of six months from the primary cancer diagnosis, the observed number of thyroid cancer, soft tissue cancer, and leukemia exceeded the number of expected cases significantly (Table 1). The SIRs were also elevated for cancers of the oropharynx, breast, urinary organs, skin (non-melanoma), and mesothelioma, but not significantly (Table 1). There were less than expected cancer cases in the uterine corpus and ovaries. For all subsequent cancers, the SIRs stratified for follow-up time were 0.75 for 0.5-4 years (95% CI 0.45-1.15), 0.98 for 5-14 years (95% CI 0.72-1.30), and 1.40 (95% CI 1.07-1.78) for more than 15 years after diagnosis of AGCT. The SIR was higher for patients who were less than 50 years of age at primary diagnosis (SIR 1.31, 95% CI 0.96-1.75). The results were largely similar when also second primary cancer cases diagnosed within six months after AGCT were included, with the exception of uterine cancer.

The SIR for breast cancer after AGCT was 1.4 after at least five years of primary cancer diagnosis (Table 2). Subsequent breast cancer was somewhat more

common in patients who were at least 50 years old at the time of AGCT diagnosis (SIR 1.31, 95% CI 0.86-1.91). The SIR was only elevated in localized breast cancer (SIR 1.36, 95% CI 0.86-2.02), as opposed to non-localized breast cancer (SIR 0.83, 95% CI 0.42-1.46). In patients who had breast cancer diagnosed primarily, there were 25 cases of subsequent AGCTs during follow-up (Table 3). The SIR for AGCT after breast cancer was 1.59 (95% CI 1.04-2.29), and increased with time since breast cancer diagnosis to 2.28 (95% CI 0.98-4.41) in the follow-up category of 15 years or more. For age below 50 years at breast cancer diagnosis the SIR was 2.10 (95 % CI 1.09-3.59).

From the cancers diagnosed within six months of AGCT, uterine cancer accounted for 33% (n=5), digestive organs 27% (n=4), and breast cancer 13% (n=2) of these cases. Other malignancies reported within this follow-up period included cancers of the urinary tract, and lymphoid/hematopoietic tissue. After uterine cancer, AGCT was diagnosed in 20 women within six months (SIR 4.99, 95% CI 3.18-7.37), whereas two women developed AGCT more than 6 months after primary uterine cancer diagnosis. All women with uterine cancer and subsequent AGCT were at least 50 years of age at the time of the uterine cancer diagnosis (SIR 6.21, 95% CI 4.09-9.42).

Discussion

The indolent course, relatively low disease-related mortality and estrogen-secreting capability of AGCT result in a clinically relevant lifetime risk for developing a second primary cancer. On the other hand, the etiological factors of AGCT are largely unknown, and a common predisposing factor may exist behind

AGCT and other hormone-related cancers. To our knowledge, this is the largest and first study since Björkholm et al. in 1980¹¹ to analyze all second primary malignancies among AGCT patients. In our study, women with AGCT had a 9% increased risk of developing a new primary malignancy as compared with the general population. If cancers diagnosed within six months after the primary tumor were included, the risk was significantly increased by 19%. The large difference in these figures is mainly explained by the presence of concomitant endometrial cancer, but the significant number of cancers of the digestive organs diagnosed within six months of AGCT most likely also reflects the increased surveillance among cancer patients in general.

Two recent publications have described the incidence of endometrial cancer and breast cancer among patients with AGCT^{6, 10}. Van Meurs et al. found a 6% rate of endometrial cancer concomitant with the diagnosis of AGCT, but no increased risk for endometrial abnormalities in the median follow-up time of 10 years after AGCT for patients not having undergone hysterectomy⁶. Other population-based studies have reported 5-8% rates of concomitant endometrial cancer^{8, 9, 11}, and we reported similar rates in a large, single-institute patient cohort¹⁶. In the current population-based registry cohort, the rate was 2.5% when patients diagnosed primarily with either AGCT or uterine cancer and a subsequent uterine cancer or AGCT within six months of primary diagnosis were included. This relatively low rate may reflect a proportion of previously hysterectomized patients, since they could not be excluded from the original cancer registry data. This would also explain the higher incidence in hospital-based cohorts, as solely patients with endometrial sample available have been evaluated.

We found an increased risk for breast cancer both before and after diagnosis of AGCT, although the risk was significant only before AGCT. This is a similar finding

to the smaller Danish, Israeli and US studies where the rate of breast cancer among AGCT patients was 5-10%^{9, 10, 17}. In our study, the rate of breast cancer was 6.9% among all women with AGCT. After AGCT, the risk was confined to localized breast cancers, which may indicate towards surveillance bias, i.e. the increased frequency and intensity of clinical follow-up and examination among patients with previously diagnosed cancer. There was a relatively long latency between breast cancer and AGCT regardless of which cancer was the first primary tumor, which does not support genetic susceptibility. AGCT is neither associated with any of the known predisposing mutations to breast cancer such as BRCA1 and BRCA2 mutations, nor is the FOXL2 mutation pathognomonic to AGCT present in breast carcinoma^{1, 18}. In the present study, the risk for subsequent AGCT in breast cancer patients was significantly increased in women who were younger than 50 years at primary diagnosis, which probably reflects the long follow-up time, as the latency between the cancers was also long. Shared etiological factors such as obesity, parity, and hormonal environment offer a possible explanation for the increased incidence of breast cancer and AGCT among same women. Obesity represents a hyperestrogenic state and is a known risk factor for breast cancer¹⁹, and has been suggested as a risk factor for AGCT⁴. In post-menopausal women, breast cancer risk is around twice as high in those with the highest sex hormone levels compared to those with the lowest²⁰. Parity, on the other hand, is a protective factor in both breast and ovarian cancer^{21, 22}.

The effects of primary cancer treatment may influence the development of second primary AGCT. Selective estrogen receptor modulators (SERMs) such as tamoxifen are used to treat hormone-receptor positive breast cancer, and three case reports have linked antecedent tamoxifen use with the development of AGCT²³⁻²⁵. Furthermore, aromatase inhibitors such as letrozole are used in the treatment of both

postmenopausal breast cancer and AGCT^{26, 27}. However, further evidence is warranted to establish a causal link between hormonal breast cancer treatment and the development of AGCT.

Similarly to an earlier study, we found an increased risk for thyroid cancer among patients with previous AGCT, but it should be noted that the number of cases is rather small in both studies¹¹. It has been proposed that female hormones, reproductive factors, and obesity also play a role in thyroid cancer pathogenesis, but there are no consistent data linking ovarian and thyroid cancer^{28, 29}. *DICER1* germline mutation carriers have a predisposition to both thyroid cancer and sex cord-stromal, particularly Sertoli-Leydig cell tumors^{30, 31}. Cancer registry data are not, however, molecularly validated, and there is a possibility that some of the tumors identified as AGCT may actually represent other sex cord-stromal tumors.

We also found significantly increased SIRs for soft tissue cancer and leukemia after AGCT. The development of secondary soft tissue sarcoma is strongly associated with radiation exposure from radiotherapy, especially after breast cancer^{32, 33}. No association between female reproductive factors and the development of soft tissue cancer has been detected, but the studies in this field are scarce³⁴. As nowadays radiotherapy is rarely used in the treatment of AGCT, the increased SIR for soft tissue cancer is most likely related to shared risk factors. Furthermore, radiotherapy for ovarian cancer is known to be associated with bladder carcinoma, but in our series, the SIR for bladder cancer was not significantly elevated after AGCT³⁵. Adjuvant therapy is used in the management of metastatic or recurrent AGCT, and presently consists of platinum-based chemotherapeutic agents or more recently, hormonal treatments^{26, 36}. Late effects of chemotherapy may include increased risk for leukemia, and most likely explains the high incidence of this cancer among patients with

previous AGCT^{12, 14}. Two large population-based studies on second malignancies after ovarian cancer of any type both reported significantly elevated SIRs for cancers of the colon, rectum, lung, breast, bladder, and thyroid, as well as for leukemia, and the risk for subsequent cancer development was associated with older age, chemo- and radiotherapy^{12, 35}.

This is the largest study to date in analyzing the risk for other primary malignancies associated with AGCT. The strengths of this study are the reliable and comprehensive cancer registry incidence data, and the long observation period of over 40 years. The rarity and the lack of molecular validation of AGCT, as well as of individual data such as parity, BMI, or use of hormonal therapies are limiting factors in this analysis.

In conclusion, we found a slightly elevated risk for overall second malignancy, particularly thyroid and soft tissue cancer, and leukemia. Partly these excesses may result from carcinogenic treatments for AGCT. The increased incidence of AGCT and breast cancer among the very same patients may indicate shared hormonal etiology. Earlier studies have concluded that breast cancer patients have a higher incidence of second primary ovarian cancer, particularly when diagnosed before 50 years of age; this patient group might benefit from regular gynecological surveillance³⁷⁻³⁹. This seems to be true also for AGCT after breast cancer, which should be recognized in patient counseling and long-term clinical follow-up after the primary tumor.

248

249

250 **Acknowledgements** We thank Tiina Hakanen for invaluable assistance with the
251 cancer registry data. This study received funding from the Finnish Cancer Foundation
252 and University of Helsinki Research Funds.

253

254 The authors declare no conflict of interest.

255

256

257

References

1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(6):1180-9.
2. Bryk S, Pukkala E, Martinsen JI, et al. Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953-2012: a longitudinal cohort study. *BJOG*. 2017;124(1):143-9.
3. Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2010;23(11):1477-85.
4. Boyce EA, Costaggini I, Vitonis A, et al. The epidemiology of ovarian granulosa cell tumors: a case-control study. *Gynecol Oncol*. 2009;115(2):221-5.
5. Chen T, Surcel HM, Lundin E, et al. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2011;20(2):324-36.
6. van Meurs HS, Bleeker MC, van der Velden J, et al. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. *Int J Gynecol Cancer*. 2013;23(8):1417-22.
7. Ayhan A, Salman MC, Velipasaoglu M, et al. Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases. *J Gynecol Oncol*. 2009;20(3):158-63.
8. Unkila-Kallio L, Tiitinen A, Wahlström T, et al. Reproductive features in women developing ovarian granulosa cell tumour at a fertile age. *Hum Reprod*. 2000;15(3):589-93.
9. Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. *Gynecol Oncol*. 1983;15(2):278-86.
10. Hammer A, Lauszus FF, Petersen AC. Ovarian granulosa cell tumor and increased risk of breast cancer. *Acta Obstet Gynecol Scand*. 2013;92(12):1422-5.
11. Björkholm E, Silfverswärd C. Granulosa- and theca-cell tumors. Incidence and occurrence of second primary tumors. *Acta Radiol Oncol*. 1980;19(3):161-7.
12. Hung YP, Liu CJ, Hu YW, et al. Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study. *Medicine*. 2015;94(38):e1626.
13. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *Journal of the National Cancer Institute*. 2015;107(2).
14. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. *N Engl J Med*. 1999;340(5):351-7.
15. Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic Cancer Registries - an overview of their procedures and data comparability. *Acta Oncol*. 2017:1-16.

16. Bryk S, Farkkila A, Butzow R, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. *Int J Gynecol Cancer*. 2015;25(1):33-41.
17. Meisel JL, Hyman DM, Jotwani A, et al. The role of systemic chemotherapy in the management of granulosa cell tumors. *Gynecol Oncol*. 2015;136(3):505-11.
18. Shah SP, Kϑbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. *N Engl J Med*. 2009;360(26):2719-29.
19. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. *BMJ*. 2017;356:j477.
20. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *Journal of the National Cancer Institute*. 2002;94(8):606-16.
21. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. *Lancet*. 1994;344(8932):1250-4.
22. Layde PM, Webster LA, Baughman AL, et al. The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group. *Journal of clinical epidemiology*. 1989;42(10):963-73.
23. Gherman RB, Parker MF, Macri CI. Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. *Obstetrics and gynecology*. 1994;84(4 Pt 2):717-9.
24. Abahssain H, Kairouani M, Gherman R, et al. Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer. *World journal of surgical oncology*. 2010;8:67.
25. Tanaka T, Kato T, Ohmichi M. Granulosa cell tumor of the ovary after long-term use of tamoxifen and toremifene. *The journal of obstetrics and gynaecology research*. 2012;38(12):1379-84.
26. van Meurs HS, van Lonkhuijzen LR, Limpens J, et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. *Gynecol Oncol*. 2014;134(1):196-205.
27. Schiavon G, Smith IE. Status of adjuvant endocrine therapy for breast cancer. *Breast cancer research : BCR*. 2014;16(2):206.
28. Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. *Cancer Causes Control*. 1999;10(2):143-55.
29. Zhu J, Zhu X, Tu C, et al. Parity and thyroid cancer risk: a meta-analysis of epidemiological studies. *Cancer Med*. 2016;5(4):739-52.
30. Rutter MM, Jha P, Schultz KA, et al. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. *J Clin Endocrinol Metab*. 2016;101(1):1-5.
31. Stewart CJ, Charles A, Foulkes WD. Gynecologic Manifestations of the DICER1 Syndrome. *Surgical pathology clinics*. 2016;9(2):227-41.
32. Fletcher CD. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. *Histopathology*. 2014;64(1):2-11.
33. Virtanen A, Pukkala E, Auvinen A. Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. *Int J Cancer*. 2006;118(4):1017-21.

34. Fioretti F, Tavani A, Gallus S, et al. Menstrual and reproductive factors and risk of soft tissue sarcomas. *Cancer*. 2000;88(4):786-9.
35. Travis LB, Curtis RE, Boice JD, Jr., et al. Second malignant neoplasms among long-term survivors of ovarian cancer. *Cancer research*. 1996;56(7):1564-70.
36. Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. *Clinical oncology*. 1998;10(4):242-5.
37. Molina-Montes E, Pollan M, Payer T, et al. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). *Gynecol Oncol*. 2013;130(2):340-5.
38. Kirova YM, De Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different treatment modalities. *Br J Cancer*. 2008;98(5):870-4.
39. Hall HI, Jamison P, Weir HK. Second primary ovarian cancer among women diagnosed previously with cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2001;10(9):995-9.

Figure legends

Figure 1. Incidence of adult-type ovarian granulosa cell tumors (AGCTs) in Finland in 1968-2013, with a logarithmic trend line (dotted).

Table 1. Risk of subsequent primary malignancies among Finnish women with previous adult-type ovarian granulosa cell tumor (AGCT) in 1968-2013, by site.

Second primary tumor site	Observed	Expected	SIR	95% CI	p-value
All	137	114.7	1.19	1-1.41	0.04
All, diagnosis within 6 months of AGCT	15	3.00	5.00	2.80-8.23	<0.001
All, diagnosis > 6 months after AGCT	122	111.7	1.09	0.91-1.3	0.33
Mouth, pharynx	3	1.7	1.76	0.57-5.45	0.33
Digestive organs	24	25.7	0.93	0.63-1.39	0.74
Respiratory organs	5	6.3	0.79	0.33-1.90	0.60
Skin, melanoma	3	3.0	0.99	0.32-3.06	0.98
Skin, non-melanoma	9	4.8	1.86	0.97-3.58	0.06
Soft tissues	3	0.7	4.13	1.33-12.8	0.01
Breast	38	30.2	1.26	0.92-1.73	0.15
Female genitalia	5	14.3	0.35	0.15-0.84	0.02
Corpus uteri	0	7.1	0.00	0.00-0.52	0.01
Ovary	1	4.3	0.23	0.01-1.30	0.18
Cervix uteri	2	1.3	1.49	0.18-5.38	0.89
Other	2	1.5	1.38	0.17-4.98	0.97
Urinary organs	8	5.6	1.43	0.71-2.86	0.31
Bladder and urinary tract	3	2.4	1.27	0.26-3.73	0.92
Brain, central nervous system	3	3.9	0.76	0.25-2.36	0.64
Thyroid gland	6	1.8	3.42	1.54-7.62	0.003
Lymphoid and hematopoietic tissue	11	9.6	1.15	0.64-2.07	0.65
Leukemia	6	2.2	2.67	0.98-5.82	0.03
Other or not defined	3	3.4	0.88	0.28-2.72	0.82

SIR= standardized incidence ratio, CI = confidence interval. Sites with < 3 observed cases are excluded, with the exception of cancers of the female genitalia.

Table 2. Risk of subsequent breast cancer among Finnish women with previous adult-type granulosa cell tumor (AGCT) in 1968-2013, by age at and time since AGCT diagnosis, and breast cancer invasion.

	Observed	Expected	SIR	95% CI	p-value
All	40	31	1.29	0.93-1.73	0.11
All, diagnosis > 6 months after AGCT	38	30.2	1.26	0.9-1.7	0.15
Follow-up time (years)					
0-4	6	6.9	0.87	0.34-1.76	0.73
5-14	17	12.3	1.38	0.82-2.15	0.18
≥15	15	10.9	1.37	0.79-2.19	0.22
Age at AGCT diagnosis					
<50	14	11.9	1.18	0.66-1.91	0.54
≥50	24	18.3	1.31	0.86-1.91	0.18
Breast cancer invasion ¹					
Localized	21	15.5	1.36	0.86-2.02	0.16
Non-localized	10	12.0	0.83	0.42-1.46	0.56

AGCT= adult-type ovarian granulosa cell tumor, SIR= standardized incidence ratio, CI = confidence interval.

¹Invasion status unknown in seven cases

Table 3. Risk of subsequent adult-type granulosa cell tumors (AGCTs) among Finnish women with breast cancer in 1968-2013, by age at and time since breast cancer diagnosis.

	Observed	Expected	SIR	95% CI	p-value
All	28	16.6	1.69	1.14-2.4	0.006
All, diagnosis > 6 months after breast cancer	25	15.7	1.59	1.04-2.29	0.02
Follow-up time (years)					
0-4	8	5.9	1.35	0.62-2.52	0.39
5-14	10	6.8	1.48	0.74-2.59	0.22
≥15	7	3.1	2.28	0.98-4.41	0.03
Age at breast cancer diagnosis					
<50	11	5.2	2.10	1.09-3.59	0.01
≥50	14	10.5	1.33	0.75-2.16	0.28

SIR= standardized incidence ratio, CI = confidence interval.

Figure 1. Incidence of adult-type ovarian granulosa cell tumors (AGCTs) in Finland in 1968-2013, with a logarithmic trend line (dotted).